Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 13/20 | 0.48 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785773 | 1.00 | SLC5A2 (0.48) | SLC5A2PYGLSLC29A1SLC5A1 | |
| SCHEMBL6791154 | 0.80 | SLC5A2 (0.49) | SLC5A2PYGLSLC29A1SLC5A1 | |
| SCHEMBL6790264 | 0.80 | SLC5A2 (0.49) | SLC5A2PYGLSLC29A1SLC5A1 | |
| SCHEMBL6931690 | 0.80 | SLC5A2 (0.49) | SLC5A2PYGLSLC29A1SLC5A1 | |
| SCHEMBL6788997 | 0.79 | SLC5A2 (0.47) | SLC5A2PYGL | |
| SCHEMBL6788460 | 0.79 | SLC5A2 (0.47) | SLC5A2PYGL | |
| SCHEMBL6789429 | 0.79 | SLC5A2 (0.45) | SLC5A2PYGLSLC5A1 | |
| SCHEMBL6789918 | 0.79 | SLC5A2 (0.46) | SLC5A2PYGL | |
| SCHEMBL6789913 | 0.79 | SLC5A2 (0.46) | SLC5A2PYGL | |
| SCHEMBL6796002 | 0.79 | SLC5A2 (0.45) | SLC5A2PYGLSLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | disclosed |
| CN-1527836-A | Antiviral agents for treatment of flaviviridae infections | — | 2004-09-08 | — | — | CN | disclosed |
| EP-1366055-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Pharmasset Limited (BB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | SLC5A2 309/4885PYGL 81/4885SLC29A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.